Tarek M. Mekhail, MD
Medical Director (Thoracic Cancer), Medical Oncologist
Cancer

Overview
Dr. Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd is board-certified in internal medicine, hematology and oncology. Dr. Mekhail serves as medical director of the Thoracic Cancer Program at the Florida Hospital Cancer Institute. He joined the team from the Cleveland Clinic where he was the director of the Lung Cancer Medical Oncology Program. Dr. Mekhail completed his medical degree at Cairo University in 1988, then went on to complete his medical training in the United Kingdom, where he earned fellowships of the Royal College of Surgeon of Edinburgh and Ireland. He completed his medical oncology fellowship at the Cleveland Clinic in Cleveland, Ohio. He is an associate professor at the University of Central Florida. Dr. Mekhail's extensive experience in the field of lung cancer is bolstered by his many awards, including being voted one of the Best Doctors in America in 2007-2008, 2008-2009 and 2009-2010.
Articles
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
JOURNAL OF CLINICAL MEDICINE
2023
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial
NATURE MEDICINE
2022
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer
Expert review of anticancer therapy
2022
GEMSTONE-302: "If you keep doing the same thing you get the same result"
CHINESE CLINICAL ONCOLOGY
2022
Langerhans Cell Histiocytosis Associated With Renal Cell Carcinoma Is it an Indolent Phenomenon or a More Ominous Pathologic Process?
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
2022
A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors
JOURNAL OF IMMUNOTHERAPY
2022
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer A Phase 1/2 Open-label Nonrandomized Clinical Trial
JAMA ONCOLOGY
2021
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
CANCER DISCOVERY
2021
Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors
ANNALS OF ONCOLOGY
2021
Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy
ANNALS OF ONCOLOGY
2021
Education & Training
Education
Cairo University Egypt
Residency
Cleveland Clinic Foundation Ohio
Fellowship
Cleveland Clinic Foundation Ohio
Specialty
Medical Oncology
Board Certifications
American Board of Internal Medicine